Baptist Health South Florida

Scholarly Commons @ Baptist Health South Florida
All Publications
1-11-2020

What a Blood Bath! Andexxa® Makes a Splash! Current Trends in
Anticoagulation Reversal
Marianela Robainas
South Miami Hospital, MarianelaR@baptisthealth.net

Follow this and additional works at: https://scholarlycommons.baptisthealth.net/se-all-publications
Part of the Chemicals and Drugs Commons, and the Pharmacy and Pharmaceutical Sciences
Commons

Citation
Robainas, Marianela, "What a Blood Bath! Andexxa® Makes a Splash! Current Trends in Anticoagulation
Reversal" (2020). All Publications. 3374.
https://scholarlycommons.baptisthealth.net/se-all-publications/3374

This Conference Lecture -- Open Access is brought to you for free and open access by Scholarly Commons @
Baptist Health South Florida. It has been accepted for inclusion in All Publications by an authorized administrator
of Scholarly Commons @ Baptist Health South Florida. For more information, please contact
Carrief@baptisthealth.net.

What a Blood Bath!
®
Andexxa makes a
Splash! Current Trends in
Anticoagulation Reversal
Marianela Robainas, PharmD
PGY-1 Pharmacy Resident
South Miami Hospital
Baptist Health of South Florida
1

Objectives


Discuss various pharmacological management
options for anticoagulation reversal



Review andexanet alfa (Andexxa®) prescribing
information and examine its role in the
management of anticoagulation reversal



Describe the role of the pharmacist in the
management of anticoagulation reversal
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Background


Anticoagulants are important for preventing and treating blood
clots but are associated with an increased risk of bleeding



In 2013 and 2014, warfarin was responsible for:







32% of estimated emergency room visits for all adverse drug events
(ADEs) among older adults
36% of emergent hospitalizations for all ADEs among older adults
Warfarin, rivaroxaban, and dabigatran were in the top 10 most common
causes of ADEs resulting in emergency department visits

In 2017:




Bleeding from oral anticoagulants resulted in approximately 235,000
emergency department visits
Direct Oral Anticoagulants (DOACs) contributed to approximately 40% of
estimated oral anticoagulant bleeding visits
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Adverse Drug Events from Specific Medicines. Center of Disease Control (CDC). 2010.

Anticoagulation Reversal
Considerations


Risks versus benefits



Indication and mechanism of action



Patient’s presentation



Severity of bleeding



Available agents currently on the market
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Anticoagulation Agents and
Antidotes
Agent

Antidotes

Warfarin

Vitamin K, Prothrombin
Complex Concentrate (PCC)

Unfractionated Heparin (UFH)

Protamine, PCC

Low Molecular Weight Heparin (LMWH)

Protamine, PCC

Fondaparinux

PCC

Direct Thrombin Inhibitor (DI)
• Dabigatran

Idarucizumab, PCC

Oral Factor Anti-Xa Inhibitors
• Apixaban
• Rivaroxaban
• Edoxaban

Andexanet Alfa*, PCC

*Andexanet alfa is only approved for the reversal of apixaban and rivaroxaban
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International Journal of Cardiology. 2016; 214: 292-298.

Clotting Cascade
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Clinical Medicine. 2018; 18(4): 314–319.

PCC (KCENTRA®)


FDA indication: urgent reversal of vitamin K antagonist
therapy in adult patients with



Acute major bleeding or
Need for an urgent surgery/invasive procedure



Mechanism of action: rapidly increases plasma levels of the
vitamin K dependent factors II, VII, IX, X, as well as Proteins
C and S



Intravenous administration: administer intravenously through
a separate infusion line; no blood should enter the syringe,
due to fibrin clot formation



PCC is contraindicated in patients with:





Known anaphylaxis to PCC or any components including heparin, factors
II, VII, IX, X, proteins C and S, antithrombin III, or human albumin
Disseminated intravascular coagulation
Known heparin-induced thrombocytopenia
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Kcentra (prothrombin complex concentrate human) [prescribing information]. Kankakee, IL: CSL Behring; October 2018.

Idarucizumab (Praxbind®)


FDA indication: reversal of dabigatran in adult patients




For emergency surgery/urgent procedures
In life-threatening or uncontrolled bleeding



Mechanism of action: humanized monoclonal antibody
fragment that binds to dabigatran and its metabolites with
higher affinity



Intravenous administration: two consecutive infusions or a
bolus injection



Adverse reactions:




Thromboembolic risk
Hypersensitivity reactions
Risk of serious adverse reactions in patients with hereditary fructose
intolerance due to sorbitol excipient
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Praxbind injection (idarucizumab) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; April 2018.

Protamine


FDA indication: treatment of heparin overdose



Mechanism of action: neutralizes heparin by
forming a stable salt



Intravenous administration: slow infusion



Box warning:






Severe hypotension
Cardiovascular collapse
Non-cardiogenic pulmonary edema
Catastrophic pulmonary vasoconstriction
Pulmonary hypertension
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Protamine [prescribing information]. Lake Zurich, IL: Fresenius Kabi; December 2016.

Coagulation Laboratory Tests
Agent

Baseline
Parameters

Monitoring
Parameters

Warfarin

CBC

INR, PT

UFH

CBC

aPTT, INR

LMWH

CBC, Scr

Anti-Xa Assay

Fondaparinux

CBC, Scr

Anti-Xa Assay

Direct Thrombin Inhibitor (DI)
• Dabigatran

CBC, Scr, Tbili,
albumin, INR

aPTT, TT

Oral Factor Anti-Xa Inhibitors
• Apixaban
• Rivaroxaban
• Edoxaban

CBC, Scr, Tbili,
albumin, INR

Anti-Xa Assay

CBC: Complete blood count, Sr: Serum creatinine, Tbili: Total bilirubin, INR: International
normalized ratio, PT: Prothrombin time, aPTT: Activated partial thromboplastin time, TT: Thrombin
time, Anti-Xa Assay: Anti-factor Xa
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National Patient Safety Goal for Anticoagulant Therapy. The Joint Commission. 2018.

Assessment of Anticoagulation
Related Bleeding


History and physical examination



Vital signs



Laboratory tests



Time of last dose of anticoagulant



Intentional or unintentional overdose



Severity of bleeding



Medications
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Major Bleeding Definition


At least one of the following factors:
Criteria for Major Bleeding
Critical Site

•

•

Hemorrhage
o Intracranial
o Spinal
o Thoracic
Bleed that compromises organ function

Hemodynamic Instability

•
•
•
•

SBP <90 mmHg
Decrease in SBP >40 mmHg
MAP <65 mmHg
Additional clinical signs and other markers
of poor organ perfusion can aid in the
evaluation

Overt Bleeding

•
•

Decrease in hemoglobin ≥2 g/dL
Administration of ≥2 units of packed RBCs

SBP: Systolic blood pressure, MAP: Mean arterial pressure, RBC: Red blood cell
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Journal of the American College of Cardiology. 2017; 70(24): 3042-3067.

Guideline Recommendations
Bleeding Considered Major
Is the bleed at a critical site or life
threatening?
Yes

• Stop oral anticoagulant
• If patient is on warfarin, give
5-10 mg IV vitamin K
• Manual compression
• Supportive care
• Discontinue antiplatelet agent
• Assess comorbidities that
contribute to bleeding
• Surgical management of
bleeding site
• Suggest administering
reversal agent

No
• Stop oral anticoagulant
• If patient is on warfarin,
give 5-10 mg IV vitamin K
• Manual compression
• Supportive care
• Discontinue antiplatelet
agent
• Assess comorbidities that
contribute to bleeding
• Surgical management of
bleeding site
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Journal of the American College of Cardiology. 2017; 70(24): 3042-3067.

Guideline Recommendations
Continued
Bleeding Considered Non-major
Does the bleed require hospitalization,
surgical/procedural intervention, or transfusion?
Yes
• Stop oral anticoagulant
• If patient is on warfarin, give
2-5 mg IV vitamin K
• Manual compression
• Supportive care
• Discontinue antiplatelet
agent
• Assess comorbidities that
contribute to bleeding
• Consider surgical
management of bleeding site

No
• Consider continuing oral
anticoagulant
• Manual compression
• Supportive care
• If patient is on antiplatelet
therapy, assess for
discontinuation
• Assess comorbidities that
contribute to bleeding
• Determine if anticoagulant
dosing is appropriate
14

Journal of the American College of Cardiology. 2017; 70(24): 3042-3067.

Oral Anticoagulation Reversal
for Major Bleeding


Warfarin
 Administer 4Factor–prothrombin complex
concentrate (4F-PCC) weight based dose
• INR 2-4: 25 units/kg
• INR 4-6: 35 units/kg
• INR >6: 50 units/kg


Or low fixed-dose option
• Any major bleed: 1,000 units
• Intracranial hemorrhage: 1,500 units



If 4F-PCC not available, use plasma 10-15 ml/kg

15

Journal of the American College of Cardiology. 2017; 70(24): 3042-3067.

Oral Anticoagulation Reversal
for Major Bleeding


DI (dabigatran)







Administer idarucizumab IV 5 g
If unavailable, administer 4F-PCC or activated prothrombin
complex concentrate (aPCC) 50 units/kg IV
Consider activated charcoal for known recent ingestion (within
2-4 hours)

Factor-Xa Inhibitor (apixaban, edoxaban,
rivaroxaban)





Administer 4F–PCC 50 units/kg IV
If unavailable, aPCC 50 units/kg IV
Consider activated charcoal for known recent ingestion (within
2-4 hours)
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Journal of the American College of Cardiology. 2017; 70(24): 3042-3067.

Parenteral Anticoagulation
Reversal


UFH








LMWH





IV protamine can rapidly reverse anticoagulant effects of
heparin
1 mg of protamine will neutralize approximately 100 units of
heparin
Patient’s dose largely depends on heparin dose and duration of
infusion

IV protamine can also reverse LMWH
LMWH given within 8 hours: protamine administered in a dose
of 1 mg per 100 anti-Xa units of LMWH (maximum single
dose: 50 mg)

Fondaparinux



Fondaparinux does not bind to protamine
If uncontrollable bleeding occurs, PCC could be used at a dose
of 50 units/kg IV
17

Clinical Medicine. 2018; 18(4): 314–319.

Andexanet Alfa
®
(Andexxa )
18

Mechanism of Action


Coagulation factor xa (recombinant), inactivated-zhzo
(modified Fxa decoy protiein) exerts its procoagulant effect
by binding and sequestering the Fxa inhibitors with strong
affinity and overcoming the competition



Another procoagulant effect is its ability to bind to and inhibit
the activity of tissue factor pathway inhibitor, which
increases tissue factor-initiated thrombin generation

19
New England Journal of Medicine. 2015; 373(25): 2413-2424.

FDA Indication


Andexanet alfa
 Reversal of apixaban or rivaroxaban
 Life-threatening or uncontrolled bleeding
 Major bleeding defined as:
• Occurring in a critical site
• Hemodynamic compromise
• Decrease in hemoglobin ≥2 g/dL
• Requiring transfusion
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Andexxa (andexanet alfa) [prescribing information]. South San Francisco, CA: Portola Pharmaceuticals, Inc; December 2018.

Dose and Administration
Factor Xa
Inhibitor

Dose

<8 hours or
Unknown

Rivaroxaban

≤10 mg

Low dose

>10 mg or unknown

High dose

≤5 mg

Low dose

>5 mg or unknown

High dose

Apixaban

≥8 hours

LOW
DOSE

Dose

Initial IV Bolus

IV Infusion

Low dose

400 mg
Target rate 30 mg/min
800 mg
Target rate 30 mg/min

4 mg/min for up to 120
minutes
8 mg/min for up to 120
minutes

High dose
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Andexxa (andexanet alfa) [prescribing information]. South San Francisco, CA: Portola Pharmaceuticals, Inc; December 2018.

True or False?
If a patient took rivaroxaban 20
mg at least 12 hours ago, the
patient should receive andexanet
alfa high dose

22

Answer
If a patient took rivaroxaban 20
mg at least 12 hours ago, the
patient should receive andexanet
alfa high dose

23

Reconstitution


Determine total number of vials needed



Reconstitution instructions





100 mg vial: 10 ml sterile water
200 mg vial: 20 ml sterile water
Final concentration: 10 mg/ml



Powder must completely dissolve



Infusion requires a 0.2 or 0.22 micron in-line
polyether sulfone or equivalent low protein
binding filter



Reconstituted product is a clear to slightly yellow
solution
24
Andexxa (andexanet alfa) [prescribing information]. South San Francisco, CA: Portola Pharmaceuticals, Inc; December 2018.

Stability


DO NOT SHAKE solution as it could lead to
foaming



Vial is stable at room temperature for 24 hours



After reconstitution in an IV bag: stable at room
temperature for 8 hours



Doesn’t contain preservatives
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Andexxa (andexanet alfa) [prescribing information]. South San Francisco, CA: Portola Pharmaceuticals, Inc; December 2018.

Adverse Reactions


>10%:





Immunologic: Antibody development (6% to 17%)
Miscellaneous: Infusion-related reaction (18%)

1% to 10%:





Cardiovascular: Deep vein thrombosis (6%), ischemic
stroke (5%), acute myocardial infarction (3%),
pulmonary embolism (3%), cardiogenic shock (2%),
cardiac failure (1%)
Genitourinary: Urinary tract infection (≥5%)
Respiratory: Pneumonia (≥5%), acute respiratory failure
(1%)
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Andexxa (andexanet alfa) [prescribing information]. South San Francisco, CA: Portola Pharmaceuticals, Inc; December 2018.

True or False?
Andexanet alfa dosing is guided by
administration time and dose of
the factor Xa inhibitor
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Answer
Andexanet alfa dosing is guided by
administration time and dose of
the factor Xa inhibitor
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Warning and Precautions


No contraindications
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Andexxa (andexanet alfa) [prescribing information]. South San Francisco, CA: Portola Pharmaceuticals, Inc; December 2018.

Special Populations


Pregnancy: No adequate controlled studies



Lactation: No information regarding presence in
human milk



Pediatrics: No safety or efficacy information



Geriatrics: No observed differences in safety and
efficacy in geriatric patients in the ANNEXA-4 trial
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Andexxa (andexanet alfa) [prescribing information]. South San Francisco, CA: Portola Pharmaceuticals, Inc; December 2018.

Resuming Anticoagulation


Risks versus benefits



Severity and location of the bleed



Indication



Timing



Re-evaluate dose



Consider patient’s comorbidities



Comprehensive medication review
31

True or False?
There are no risks associated with
andexanet alfa following its
administration

32

Answer
There are no risks associated with
andexanet alfa following its
administration
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Clinical Trials


Approved under accelerated approval based on the change
from baseline anti-factor Xa in healthy volunteers



Efficacy and safety was established in a phase III trial for
apixaban and rivaroxaban in ANNEXA-A and ANNEXA-R



ANNEXA-4: multinational, single arm, open label phase
IIIb/IV study

Ongoing trial, preliminary results are published
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ANNEXA-A and ANNEXA-R


Purpose: Establish the efficacy and safety of andexanet alfa
for the reversal of anticoagulation with apixaban or
rivaroxaban in older healthy volunteers



Patient population: Healthy older volunteers were given
apixaban 5 mg twice daily or rivaroxaban 20 mg daily



Intervention: For each factor Xa inhibitor, a two-part
randomized placebo-controlled study was conducted to
evaluate andexanet alfa administered as a bolus or as a bolus
plus a 2-hour infusion



Outcome: The mean percent change in anti–factor Xa
activity from baseline
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New England Journal of Medicine. 2015; 373(25): 2413-2424.

Trial Results


Apixaban






Anti–factor Xa activity was reduced by 94% among those
who received an andexanet alfa bolus (24 participants), as
compared with 21% among those who received placebo (9
participants) (P<0.001)
Unbound apixaban concentration was reduced by 9.3 ng/ml
versus 1.9 ng/ml (P<0.001)
Thrombin generation was fully restored within 2 to 5
minutes in 100% versus 11% of the participants (P<0.001)
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New England Journal of Medicine. 2015; 373(25): 2413-2424.

Trial Results


Rivaroxaban








Anti–factor Xa activity was reduced by 92% among
those who received an andexanet alfa bolus (27
participants), as compared with 18% among those who
received placebo (14 participants) (P<0.001)
Unbound rivaroxaban concentration was reduced by
23.4 ng/ml versus 4.2 ng/ml (P<0.001)
Thrombin generation was fully restored in 96% versus
7% of the participants (P<0.001)
Effects were sustained when andexanet alfa was
administered as a bolus plus an infusion
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New England Journal of Medicine. 2015; 373(25): 2413-2424.

ANEXXA-4


Purpose: to assess the efficacy and safety of andexanet alfa
in patients with acute major bleeding occurring while taking a
factor Xa inhibitor



Inclusion criteria






≥18 years old
Acute major bleeding
Received one of the following within 18 hours: apixaban,
rivaroxaban, edoxaban, or enoxaparin at a dose ≥ 1 mg/kg/day

Patients were enrolled from April 2015 through May 2018




From July 2016 through August 2017, only patients with
intracranial hemorrhage were enrolled
After August 2017, patients with all types of bleeding except
visible, musculoskeletal, or intraarticular bleeding were enrolled
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New England Journal of Medicine. 2019; 380(14): 1326-1335.

ANEXXA-4


Outcomes:






Percent change in anti–factor Xa activity after andexanet alfa
treatment
Percentage of patients with excellent or good hemostatic
efficacy at 12 hours after the end of the infusion

Bleeding: predominantly intracranial (in 227 patients
[64%]) or gastrointestinal (in 90 patients [26%])

39

New England Journal of Medicine. 2019; 380(14): 1326-1335.

Results


Apixaban




Rivaroxaban




Median anti–factor Xa activity decreased from 149.7 ng/ml at
baseline to 11.1 ng/ml after the andexanet alfa bolus (92%
reduction; 95% confidence interval [CI], 91 to 93)
Median value decreased from 211.8 ng/ml to 14.2 ng/ml (92%
reduction; 95% CI, 88 to 94)

Enoxaparin


Median value for anti–factor Xa activity decreased from 0.48
IU/ml at baseline to 0.15 IU/ml at the end of the bolus
administration (75% reduction; 95% CI, 66 to 79)



Excellent or good hemostasis occurred in 82% of patients



Safety outcomes (within 30 days): death occurred in 49
patients (14%) and a thrombotic event in 34 patients
(10%)
40

New England Journal of Medicine. 2019; 380(14): 1326-1335.

Patient Counseling


Purpose of medication



Inform patients that reversing factor Xa inhibitor
therapy increases the risk of thromboembolic
events




Arterial and venous thromboembolic events, ischemic
events, cardiac events, and sudden death were observed
within 30 days following andexanet alfa administration

Signs and symptoms of deep venous
thromboembolism or pulmonary embolism
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Future Agents for
Anticoagulation Reversal


Cirapratang (Aripazine®)









Phase II trial
Broad-spectrum reversal agent
Mechanism of action: binds through ionic charge
interactions and removes anticoagulant from its target
Reversal includes: factor Xa inhibitors, DI, UFH, and
LMWH

Andexanet alfa (Andexxa®)


Phase II trial for the reversal of apixaban, rivaroxaban,
and edoxaban in healthy Japanese and Caucasian
patients
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Pharmacist Role


Evaluates patient’s presentation



Ensure appropriate agent and dose



Monitor for adverse effects



Monitor laboratory markers and patient’s
hemodynamic stability



Medication history



Restart anticoagulation therapy when appropriate

43

Questions?
44
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